Sending Office: Honorable Doris O. Matsui
Current Co-Sponsors: Aderholt, Brown, Budd, Butterfield, Crist, Fitzpatrick, Hastings, Jackson Lee, Lowenthal, Neguse, Pingree, Rouda, Swalwell, Walden, Welch, Young
We invite you to cosponsor bipartisan legislation to reauthorize the CW Bill Young Cell Transplantation Program (Program) and the National Cord Blood Inventory program (NCBI). These programs save lives by connecting patients with otherwise fatal blood cancers
or blood disorders to unrelated donors across the world. Authorization for the Program and NCBI expires at the end of Fiscal Year 2020. The
Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2019 (TRANSPLANT Act) would allow for continued operation and funding through 2025 without interruption.
The Program, which includes the NCBI, provides access to lifesaving bone marrow, peripheral blood stem cell (PBSC) and cord blood transplants to those living with one of the more than 70 blood cancers, sickle cell anemia, and other blood disorders for which
a transplant is the only curative option. Through the NCBI, the Health Resources and Services Administration (HRSA) supports cord blood banks that collect, store, and make available for transplant through the Program’s national registry high-quality cord blood
units. These cord blood stem units have been especially valuable in providing matches for minority patients who often face greater challenges in finding a bone marrow match.
The Program operates a national registry that includes more than 20 million potential bone marrow donors and over 254,000 units of umbilical cord blood, including more than 100,000 NCBI units. The Program helps patients navigate the complexities of the
health care system and collects the data for each of these transplants to help improve patient outcomes.
With this legislation, Congress can reauthorize these programs in a timely manner and invest in providing significant improvements to deliver the best possible transplant to every patient in need. Specifically,
the TRANSPLANT Act would:
- Reauthorize the programs through 2025 at the current authorized levels of $30 million for the Program and $23 million for the NCBI.
- Require HRSA’s Advisory Council on Blood Stem Cell Transplantation to meet at least twice a year.
- Extend requirement for the Department of Health and Human Services to review the state of the science related to regenerative medicine for the purpose of potentially including these innovative therapies in the outcomes database in the Program.
The TRANSPLANT Act is supported by The National Marrow Donor Program®(NMDP)/Be The Match®, which operates the Program. For more information or to cosponsor the legislation, please contact Christina McCauley with Ms. Matsui (Christina.Mccauley@mail.house.gov)
or Shayne Woods with Mr. Bilirakis (Shayne.Woods@mail.house.gov).
Doris O. Matsui Gus M. Bilirakis
Member of Congress Member of Congress
e-Dear Colleague version 2.0